Searchable News & Info From Reliable Online Sources.
Latest Real News From 140 News Sites Updated Every 15 Minutes.
- Games with loot boxes to get minimum 16 age rating across Europe
The new changes by the Pan-European Game Information age-ratings body (PEGI) will start from June. [TheTopNews] Read More.1 day ago - As war between Israel and Hezbollah escalates, life in Lebanon poised to get ...
[TheTopNews] Read More.1 day ago - Blast rocks Tehran amid latest wave of U.S. and Israeli airstrikesAs American and Israeli strikes pound Iran — while it attacks shipping and energy infrastructure across the Persian Gulf — U.S. President Donald Trump made a new threat to Tehran's leaders. [TheTopNews] Read More.1 day ago
- If you stop using a GLP-1 drug, do you regain the weight?
New research found little evidence of that By Mark Huffman of ConsumerAffairs March 13, 2026 A new Cleveland Clinic study of nearly 8,000 patients found that people who stop popular GLP-1 weight-loss drugs often avoid major weight regain in real-world settings. Researchers say many patients restart the medications or switch to other obesity treatments, which may help stabilize their weight. The findings contrast with earlier clinical trials that suggested patients regain more than half of the lost weight within a year after stopping the drugs. As the use of injectable GLP-1 drugs continues to rise, researchers are beginning to examine what actually happens when patients stop taking them outside tightly controlled clinical trials. A new analysis from the Cleveland Clinic suggests that, in real-world clinical practice, patients who discontinue semaglutide or tirzepatide often avoid the significant weight regain reported in earlier randomized studies. The research, published in the journal Diabetes, Obesity and Metabolism, examined nearly 8,000 adults who had started one of the injectable medications and later stopped taking it within three to 12 months. Investigators found that many patients either restarted the drug or transitioned to other weight-management treatments, helping them maintain much of their earlier weight loss. Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials, said Hamlet Gasoyan, DS, Ph.D., MPH, a researcher with the Cleveland Clinics Center for Value-Based Care Research who led the study. Study looked at nearly 8,000 patients The retrospective cohort study included 7,938 adults with obesity or overweight in Ohio and Florida who had been prescribed injectable semaglutidesold under the brand names Ozempic and Wegovyor tirzepatide, marketed as Mounjaro and Zepbound. Patients had been using the drugs to treat either obesity or type 2 diabetes. Researchers tracked the treatments patients pursued after discontinuing the medications and monitored how their weight changed during the following year. Before stopping treatment, patients generally experienced meaningful weight loss, though results varied by condition. Patients using the medications to treat obesity lost an average of 8.4% of their body weight before discontinuation and regained about 0.5% of their weight one year later. Those taking the drugs for type 2 diabetes lost an average of 4.4% of their body weight before stopping treatment… [TheTopNews] Read More.1 day ago - Kentucky Launches $5 Million Roof Grant Program
Kentucky, far inland from where most hurricanes land but a place all too familiar with high winds and hail, has become the latest state to offer grants for stronger roofs. Gov. Andy Beshear announced this week that the Strengthen Kentucky … [TheTopNews] Read More.1 day ago
« Previous
1
…
69
70
71
72
73
…
111
Next »
The new changes by the Pan-European Game Information age-ratings body (PEGI) will start from June. [TheTopNews] Read More.
1 day ago
[TheTopNews] Read More.
1 day ago
As American and Israeli strikes pound Iran — while it attacks shipping and energy infrastructure across the Persian Gulf — U.S. President Donald Trump made a new threat to Tehran's leaders. [TheTopNews] Read More.
1 day ago
New research found little evidence of that By Mark Huffman of ConsumerAffairs March 13, 2026 A new Cleveland Clinic study of nearly 8,000 patients found that people who stop popular GLP-1 weight-loss drugs often avoid major weight regain in real-world settings. Researchers say many patients restart the medications or switch to other obesity treatments, which may help stabilize their weight. The findings contrast with earlier clinical trials that suggested patients regain more than half of the lost weight within a year after stopping the drugs. As the use of injectable GLP-1 drugs continues to rise, researchers are beginning to examine what actually happens when patients stop taking them outside tightly controlled clinical trials. A new analysis from the Cleveland Clinic suggests that, in real-world clinical practice, patients who discontinue semaglutide or tirzepatide often avoid the significant weight regain reported in earlier randomized studies. The research, published in the journal Diabetes, Obesity and Metabolism, examined nearly 8,000 adults who had started one of the injectable medications and later stopped taking it within three to 12 months. Investigators found that many patients either restarted the drug or transitioned to other weight-management treatments, helping them maintain much of their earlier weight loss. Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomized trials, said Hamlet Gasoyan, DS, Ph.D., MPH, a researcher with the Cleveland Clinics Center for Value-Based Care Research who led the study. Study looked at nearly 8,000 patients The retrospective cohort study included 7,938 adults with obesity or overweight in Ohio and Florida who had been prescribed injectable semaglutidesold under the brand names Ozempic and Wegovyor tirzepatide, marketed as Mounjaro and Zepbound. Patients had been using the drugs to treat either obesity or type 2 diabetes. Researchers tracked the treatments patients pursued after discontinuing the medications and monitored how their weight changed during the following year. Before stopping treatment, patients generally experienced meaningful weight loss, though results varied by condition. Patients using the medications to treat obesity lost an average of 8.4% of their body weight before discontinuation and regained about 0.5% of their weight one year later. Those taking the drugs for type 2 diabetes lost an average of 4.4% of their body weight before stopping treatment… [TheTopNews] Read More.
1 day ago
Kentucky, far inland from where most hurricanes land but a place all too familiar with high winds and hail, has become the latest state to offer grants for stronger roofs. Gov. Andy Beshear announced this week that the Strengthen Kentucky … [TheTopNews] Read More.
1 day ago
The Searchable USWebDaily.com and TheTopNews NewsBank Helps You Be Better Informed, Faster! Spread The Word.
